Serum sclerostin as a marker of microvascular and macrovascular complications among children and adolescents with type 1 diabetes mellitus.

Journal: Pediatric nephrology (Berlin, Germany)
Published Date: May 12, 2025

Abstract

BACKGROUND: Uncontrolled diabetes mellitus (DM) accelerates atherosclerosis and vascular diseases, leading to micro- and macrovascular complications. Early cardiac and kidney involvement necessitates an early biomarker. Sclerostin is a Wnt-signaling inhibitor, having a pathophysiological role in vasculopathy, and could be used as a vasculopathy marker. Nevertheless, few data are available in pediatric patients with type 1 diabetes mellitus (T1DM). We aimed at assessing its serum level, and relation to diabetic microvascular and macrovascular complications.

Authors

  • Dina E Sallam
    Department of Pediatrics and Pediatric Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. dinaebrahim2008@med.asu.edu.eg.
  • Yasmine Ibrahim Mahmoud Elhenawy
    Department of Pediatric, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Aya Mohamed Abdullah Ahmed
    Department of Pediatric, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Sara Ibrahim Abdelfattah Taha
    Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Eman Mohamed Elsayed
    Department of Pediatric, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals